Latest News | Windlas Biotech IPO Subscribed 22.46 Times on Final Day

Get latest articles and stories on Latest News at LatestLY. The initial public offer of Windlass Biotech, a manufacturer of pharmaceutical formulations, was subscribed 22.46 times on Friday, the closing day for subscription.

New Delhi, Aug 6 (PTI) The initial public offer of Windlass Biotech, a manufacturer of pharmaceutical formulations, was subscribed 22.46 times on Friday, the closing day for subscription.

The three-day IPO received bids for 13,77,39,750 shares against 61,36,252 shares on offer, as per NSE data.

Also Read | Hiring Activity in India Touches All-Time High in July 2021, Indicates Strong Revival of Economic Growth: Report.

The category for Qualified Institutional Buyers(QIBs) was subscribed 24.40 times, non-institutional investors 15.73 times, and retail individual investors(RIIs) 24.27 times.

The initial public offer had a fresh issue of up to Rs 165 crore and an offer for sale of up to 51,42,067 equity shares.

Also Read | Samsung Galaxy Z Flip 3 & Galaxy Z Fold 3 Pre-Booking Now Open in India: Report.

The Rs 401.53-crore offer had a price range of Rs 448-460 per share.

Windlas Biotech on Tuesday raised over Rs 120 crore from anchor investors.

The proceeds from the IPO will be utilised for purchasing of equipment required for capacity expansion of the facility at Dehradun Plant-IV and addition of injectables dosage capability at the facility at Dehradun Plant-II.

It will also be used for funding incremental working capital requirements, repayment/ prepayment of certain borrowings, and general corporate purposes.

SBI Capital Markets, DAM Capital Advisors, and IIFL Securities were the managers of the offer.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)

Share Now

Share Now